EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies

Aasem Abu Shtaya, Inbal Kedar, Lily Bazak, Lina Basel-Salmon, Sarit Farage Barhom, Michal Naftali, Marina Eskin-Schwartz iD, Ohad S Birk iD, Shirley Polager-Modan, Nitzan Keidar, Gili Reznick Levi, Zohar Levi und 7 weitere

Genes · 2024

DOI: 10.3390/genes15030355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2024. Verfasst von Aasem Abu Shtaya und 18 weiteren Autor:innen. Beteiligte Einrichtung: Recanati Genetics Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva 4941492, Israel. Hauptthemen laut MEDLINE: Melanoma, Leukemia, Lymphocytic, Chronic, B-Cell, Skin Neoplasms, Thyroid Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

POT1 (Protection of Telomeres 1) is a key component of the six-membered shelterin complex that plays a critical role in telomere protection and length regulation. Germline variants in the POT1 gene have been implicated in predisposition to cancer, primarily to melanoma and chronic lymphocytic leukemia (CLL). We report the identification of POT1 p.(I78T), previously ranked with conflicting interpretations of pathogenicity, as a founder pathogenic variant among Ashkenazi Jews (AJs) and describe its unique clinical landscape. A directed database search was conducted for individuals referred for genetic counselling from 2018 to 2023. Demographic, clinical, genetic, and pathological data were collected and analyzed. Eleven carriers, 25 to 67 years old, from ten apparently unrelated families were identified. Carriers had a total of 30 primary malignancies (range 1–6); nine carriers (82%) had recurrent melanoma between the ages of 25 and 63 years, three carriers (27%) had desmoid tumors, three (27%) had papillary thyroid cancer (PTC), and five women (63% of female carriers) had breast cancer between the ages of 44 and 67 years. Additional tumors included CLL; sarcomas; endocrine tumors; prostate, urinary, and colorectal cancers; and colonic polyps. A review of a local exome database yielded an allelic frequency of the variant of 0.06% among all ethnicities and of 0.25% in AJs. A shared haplotype was found in all carriers tested. POT1 p.(I78T) is a founder disease-causing variant associated with early-onset melanoma and additional various solid malignancies with a high tumor burden. We advocate testing for this variant in high-risk patients of AJ descent. The inclusion of POT1 in germline panels for various types of cancer is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaLeukemia, Lymphocytic, Chronic, B-CellSkin NeoplasmsThyroid NeoplasmsMaleHumansFemaleAdultMiddle AgedAgedTelomere-Binding ProteinsShelterin Complex

Stichwörter der Autor:innen

AshkenaziPOT1breast cancercancerdesmoidmelanoma

Substanzen

Telomere-Binding ProteinsPOT1 protein, humanShelterin Complex

Autor:innen und Institutionen

  • Recanati Genetics Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva 4941492, Israel.
  • Unit of Gastroenterology, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Felsenstein Medical Research Center, Petach Tikva 4920235, Israel.
  • Pediatric Genetic Unit, Schneider Children's Medical Center of Israel, Petch Tikva 4920235, Israel.
  • Clalit Genomic Center, Petach Tikva 5252247, Israel.

ORCID-Profile: Marina Eskin-Schwartz, Ohad S Birk, Yael Goldberg

Zitieren

APA

Abu Shtaya, A., Kedar, I., Bazak, L., Basel-Salmon, L., Barhom, S. F., Naftali, M., Eskin-Schwartz, M., Birk, O. S., Polager-Modan, S., Keidar, N., Reznick Levi, G., Levi, Z., Yablonski-Peretz, T., Mahamid, A., Segol, O., Matar, R., Bareli, Y., Azoulay, N., & Goldberg, Y. (2024). A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies. Genes. https://doi.org/10.3390/genes15030355

Vancouver

Abu Shtaya A, Kedar I, Bazak L, Basel-Salmon L, Barhom SF, Naftali M, et al. A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies. Genes. 2024. doi:10.3390/genes15030355

BibTeX
@article{AbuShtaya2024,
  author = {Abu Shtaya, Aasem and Kedar, Inbal and Bazak, Lily and Basel-Salmon, Lina and Barhom, Sarit Farage and Naftali, Michal and Eskin-Schwartz, Marina and Birk, Ohad S and Polager-Modan, Shirley and Keidar, Nitzan and Reznick Levi, Gili and Levi, Zohar and Yablonski-Peretz, Tamar and Mahamid, Ahmad and Segol, Ori and Matar, Reut and Bareli, Yifat and Azoulay, Noy and Goldberg, Yael},
  title = {A POT1 Founder Variant Associated with Early Onset Recurrent Melanoma and Various Solid Malignancies},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15030355}
}
Kostenlos starten →